W
WAVEMAN · COMPANY
VIR · Vir Biotechnology, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

VIR

Vir Biotechnology, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001706431
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$1.2M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
125
13F, latest reported quarter
REVENUE GROWTH
-7.6%
XBRL, annual
NET MARGIN
-638.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$1.2M over 180 days
below 62% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
125 funds added or opened last quarter
more than 74% of Pharma & Biotech
REVENUE
-7.6% year over year
below 69% of Pharma & Biotech
MARGIN
-638.9% net margin
below 84% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$1.2M across 4 people in 180 days.
125 funds added or opened positions in the latest 13F quarter, of 239 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +130.0%
+130.0%12M
-4%+41%+87%+133%2025-092025-102025-122026-032026-052026-072026-09 2025-10-08 · SB INVESTMENT ADVISERS (UK) LTD sold $2.8M2025-10-03 · SVF Endurance (Cayman) Ltd sold $2.5M2025-10-09 · SOFTBANK VISION FUND (AIV M1) L.P. sold $1.5M2025-11-25 · SVF Endurance (Cayman) Ltd sold $1.5M2025-11-24 · SVF Endurance (Cayman) Ltd sold $1.4M2025-10-20 · SVF Endurance (Cayman) Ltd sold $1.4M2025-12-01 · SVF Endurance (Cayman) Ltd sold $1.1M2025-10-23 · SB INVESTMENT ADVISERS (UK) LTD sold $924.8K2025-10-22 · SB INVESTMENT ADVISERS (UK) LTD sold $887.2K2025-11-26 · SOFTBANK VISION FUND (AIV M1) L.P. sold $817.5K2025-10-21 · SVF Endurance (Cayman) Ltd sold $691.0K2026-04-06 · De Backer Marianne sold $664.6K2025-10-06 · SVF Endurance (Cayman) Ltd sold $420.8K2026-02-24 · SATO VICKI L sold $411.2K2025-10-07 · SB INVESTMENT ADVISERS (UK) LTD sold $403.9K2025-10-27 · SB INVESTMENT ADVISERS (UK) LTD sold $401.7K2025-11-28 · SOFTBANK VISION FUND (AIV M1) L.P. sold $396.0K2025-10-24 · SB INVESTMENT ADVISERS (UK) LTD sold $278.3K2026-05-01 · SATO VICKI L sold $221.1K2026-03-02 · SATO VICKI L sold $207.1K2026-04-01 · SATO VICKI L sold $199.5K2026-02-02 · SATO VICKI L sold $169.6K2025-10-28 · SVF Endurance (Cayman) Ltd sold $158.9K2026-02-23 · De Backer Marianne sold $141.8K2026-02-24 · De Backer Marianne sold $140.7K2026-02-25 · de Verneuil Vanina sold $134.5K2025-12-01 · SATO VICKI L sold $132.0K2026-01-02 · SATO VICKI L sold $130.5K2025-10-01 · SATO VICKI L sold $128.5K2025-11-03 · SATO VICKI L sold $124.1K2025-09-02 · SATO VICKI L sold $109.8K2025-10-15 · SVF Endurance (Cayman) Ltd sold $101.2K2025-10-16 · SVF Endurance (Cayman) Ltd sold $78.3K2026-03-23 · Sabatini Brent sold $70.3K2025-11-17 · O'Byrne Jason sold $37.8K2026-02-23 · de Verneuil Vanina sold $33.1K2026-06-01 · Napolitano Janet sold $30.2K2026-02-24 · de Verneuil Vanina sold $29.7K2026-02-25 · Eisner Mark sold $18.5K2026-02-24 · O'Byrne Jason sold $15.6K2026-02-23 · O'Byrne Jason sold $15.6K2026-02-23 · Eisner Mark sold $15.6K2026-08-25 · O'Byrne Jason filed to sell $242.6K2026-08-24 · O'Byrne Jason filed to sell $142.1K2026-08-21 · O'Byrne Jason filed to sell $245.3K2026-06-29 · Ramasastry Saira filed to sell $165.1K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $1.2M sold by insiders over 180 days, 125 funds added last quarter, $795.2K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Vir Biotechnology, Inc. insiders sold a net $1.2M of stock across 337 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Napolitano Janet
Director
SELL
2026-06-01
3,200.0
$30.2K
Sabatini Brent
SVP, Chief Accounting Officer
SELL
2026-06-01
379.0
$3.6K
SATO VICKI L
Director
SELL
2026-05-01
22,000.0
$221.1K
De Backer Marianne
President and CEO
SELL
2026-04-06
72,559.0
$664.6K
SATO VICKI L
Director
SELL
2026-04-01
22,000.0
$199.5K
337 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 332 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
20,678,283.0 sh
$210.7M
ARCH Venture Management, LLC
12,694,163.0 sh
$129.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
11,495,215.0 sh
$117.1M
SB INVESTMENT ADVISERS (UK) LTD
10,948,093.0 sh
$111.6M
STATE STREET CORP
9,964,151.0 sh
$101.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
O'Byrne Jason
FILED 2026-08-25
$242.6K
O'Byrne Jason
FILED 2026-08-24
$142.1K
O'Byrne Jason
FILED 2026-08-21
$245.3K
Ramasastry Saira
FILED 2026-06-29
$165.1K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Clinical Trials Etf
$421.4K POSITION · AS OF 2026-04-30
1.1%
iShares Genomics Immunology and Healthcare ETF
$1.7M POSITION · AS OF 2026-04-30
1.1%
Research Affiliates Deletions ETF
$267.3K POSITION · AS OF 2026-03-31
0.8%
Global X Genomics & Biotechnology ETF
$364.9K POSITION · AS OF 2026-02-28
0.7%
Nomura Healthcare Fund
$4.5M POSITION · AS OF 2026-03-31
0.7%
Invesco NASDAQ Future Gen 200 ETF
$93.6K POSITION · AS OF 2026-02-28
0.7%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 18 registered trials, 7 still enrolling or running — a status change here is dated weeks before the press release
7
Phase 1
2 ACTIVE
6
Phase 2
2 ACTIVE
3
Phase 3
2 ACTIVE
2
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Dr. Scangos
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$7.8M
$3.1M
$2.0M
-77%
+25%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$68.6M$74.2M$86.2M$1.6B
OPERATING INCOME$-479.3M$-587.2M$-684.3M$833.1M
NET INCOME$-438.0M$-522.0M$-615.1M$515.8M
EPS (DILUTED)-3.16-3.83-4.593.83
OPERATING CASH FLOW$-391.8M$-446.4M$-778.8M$1.7B
CASH$232.2M$222.9M$241.6M$848.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →